Compounds > milrinone
Page last updated: 2024-10-31

milrinone and Mitral Incompetence

milrinone has been researched along with Mitral Incompetence in 11 studies

Research Excerpts

ExcerptRelevanceReference
"To evaluate and compare the hemodynamic effects of intraoperative intravenous milrinone versus inhalational milrinone at two timepoints in patients with severe pulmonary hypertension undergoing mitral valve surgery."8.02Inhaled versus intravenous milrinone in mitral stenosis with pulmonary hypertension. ( Garg, P; Patel, J; Patel, K; Patel, S, 2021)
"Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery."6.73Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008)
"A 65-year-old female with mitral regurgitation was scheduled for the mitral valve surgery."5.32[The use of milrinone in a patient with mitral regurgitation and severe pulmonary hypertension: a case report]. ( Arisaka, H; Katori, N; Tagawa, M; Takeda, J; Yamada, T; Yamamoto, S, 2003)
"To evaluate and compare the hemodynamic effects of intraoperative intravenous milrinone versus inhalational milrinone at two timepoints in patients with severe pulmonary hypertension undergoing mitral valve surgery."4.02Inhaled versus intravenous milrinone in mitral stenosis with pulmonary hypertension. ( Garg, P; Patel, J; Patel, K; Patel, S, 2021)
"Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery."2.73Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008)
"Iloprost was administered during weaning from cardiopulmonary bypass (CPB)."2.73Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. ( Autschbach, R; Buhre, W; de Waal, EE; Flier, S; Metzelder, S; Rex, S; Rossaint, R; Schaelte, G, 2008)
"We hypothesized that mitral regurgitation (MR) would be exacerbated, cardiac index (CI) decreased, and mean pulmonary artery pressure (MPAP) increased in patients with coexisting MR during off-pump coronary artery bypass (OPCAB) anastomosis, and that milrinone could ameliorate increases in MR that occur during OPCAB anastomosis."2.71Hemodynamic changes during off-pump coronary artery bypass anastomosis in patients with coexisting mitral regurgitation: improvement with milrinone. ( Kakihana, Y; Kanmura, Y; Kawasaki, K; Mastunaga, A; Omae, T; Sakata, R; Tsuneyoshi, I, 2005)
"Milrinone was administered intravenously in successive doses of 25, 50, and 75 micrograms/kg."2.66Milrinone in the treatment of chronic cardiac failure: a controlled trial. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1985)
"Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion."1.33Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006)
"A 65-year-old female with mitral regurgitation was scheduled for the mitral valve surgery."1.32[The use of milrinone in a patient with mitral regurgitation and severe pulmonary hypertension: a case report]. ( Arisaka, H; Katori, N; Tagawa, M; Takeda, J; Yamada, T; Yamamoto, S, 2003)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19901 (9.09)18.7374
1990's0 (0.00)18.2507
2000's8 (72.73)29.6817
2010's1 (9.09)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Patel, J1
Patel, K1
Garg, P1
Patel, S1
Fleming, GA1
Murray, KT1
Yu, C1
Byrne, JG2
Greelish, JP1
Petracek, MR1
Hoff, SJ1
Ball, SK1
Brown, NJ1
Pretorius, M1
Antevil, JL1
Karavas, AN1
Selby, JH1
Yamada, T1
Katori, N1
Tagawa, M1
Yamamoto, S1
Arisaka, H1
Takeda, J1
McKinlay, KH1
Schinderle, DB1
Swaminathan, M1
Podgoreanu, MV1
Milano, CA1
Messier, RH1
El-Moalem, H1
Newman, MF1
Clements, FM1
Mathew, JP1
Chi, NH1
Huang, SC1
Yu, HY1
Chen, YS1
Wang, SS1
Hasei, M1
Uchiyama, A1
Iguchi, N1
Fujino, Y1
Nishimura, M1
Taenaka, N1
Mashimo, T1
Omae, T1
Kakihana, Y1
Mastunaga, A1
Tsuneyoshi, I1
Kawasaki, K1
Kanmura, Y1
Sakata, R1
Spoor, MT1
Geltz, A1
Bolling, SF1
Rex, S1
Schaelte, G1
Metzelder, S1
Flier, S1
de Waal, EE1
Autschbach, R1
Rossaint, R1
Buhre, W1
Likoff, MJ1
Weber, KT1
Andrews, V1
Janicki, JS1
Wilson, H1
Rocci, ML1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
RAAS, Inflammation, and Post-operative AF[NCT00141778]Phase 2/Phase 3455 participants (Actual)Interventional2005-04-30Completed
2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB[NCT00819377]Phase 2124 participants (Anticipated)Interventional2009-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Acute Renal Failure

Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.

Interventionpercentage of patients (Number)
Placebo5.4
Ramipril0.7
Spironolactone0.7

Death

The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge

Interventionpercentage of patients (Number)
Placebo1.4
Ramipril2.0
Spironolactone0

Hypokalemia

Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.

Interventionpercentage of patients (Number)
Placebo11.6
Ramipril13.8
Spironolactone6.8

Hypotension

Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.

Interventionpercentage of patients (Number)
Placebo5.4
Ramipril10.6
Spironolactone10.2

Length of Hospital Stay (Days)

(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge

Interventiondays (Mean)
Placebo6.8
Ramipril5.7
Spironolactone5.8

Postoperative Atrial Fibrillation

The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital

Interventionpercentage of patients (Number)
Placebo27.2
Ramipril27.8
Spironolactone25.9

Stroke

Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.

Interventionpercentage of patients (Number)
Placebo2.7
Ramipril1.3
Spironolactone2.0

Time to Tracheal Extubation

It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation

Interventionminutes (Mean)
Placebo1091.3
Ramipril970.1
Spironolactone576.4

Perioperative C-reactive Protein (CRP) Concentrations

C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period

,,
Interventionug/mL (Mean)
Initiation of surgeryPostoperative day 1Postoperative day 2Postoperative day 3Postoperative day 4
Placebo4.151.4134.8128.394.1
Ramipril4.349.9131.0164.8105.2
Spironolactone3.964.3127.8189.4126.5

Perioperative Interleukin(IL)-6 Concentrations

Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period

,,
Interventionpg/ml (Mean)
Initiation of surgery30min intraop60min intraopPostopPostoperative day 1Postoperative day 2
Placebo4.712.015.6130.0119.0100.3
Ramipril4.620.528.8202.1171.095.5
Spironolactone6.611.317.4145.7164.9109.6

Perioperative Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations

Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period

,,
Interventionng/mL (Mean)
Initiation of surgery30min intraop60min intraopPostopPostoperative day 1Postoperative day 2
Placebo19.619.221.036.455.228.1
Ramipril16.219.722.038.947.925.7
Spironolactone17.317.320.134.048.931.0

Trials

4 trials available for milrinone and Mitral Incompetence

ArticleYear
Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery.
    Circulation, 2008, Oct-14, Volume: 118, Issue:16

    Topics: Adult; Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiotonic Agents; Coronary Disease;

2008
Hemodynamic changes during off-pump coronary artery bypass anastomosis in patients with coexisting mitral regurgitation: improvement with milrinone.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:1

    Topics: Adrenergic alpha-Agonists; Aged; Anesthesia; Cardiac Output; Cardiotonic Agents; Coronary Artery Byp

2005
Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial.
    Acta anaesthesiologica Scandinavica, 2008, Volume: 52, Issue:1

    Topics: Administration, Inhalation; Aged; Cardiac Output, Low; Cardiopulmonary Bypass; Catheterization, Swan

2008
Milrinone in the treatment of chronic cardiac failure: a controlled trial.
    American heart journal, 1985, Volume: 110, Issue:5

    Topics: Administration, Oral; Aged; Atrial Fibrillation; Cardiomyopathy, Dilated; Chronic Disease; Clinical

1985

Other Studies

7 other studies available for milrinone and Mitral Incompetence

ArticleYear
Inhaled versus intravenous milrinone in mitral stenosis with pulmonary hypertension.
    Asian cardiovascular & thoracic annals, 2021, Volume: 29, Issue:3

    Topics: Administration, Inhalation; Administration, Intravenous; Adult; Antihypertensive Agents; Cardiopulmo

2021
Use of a hybrid operating room to diagnose and treat delayed coronary spasm after mitral valve repair.
    The Journal of thoracic and cardiovascular surgery, 2010, Volume: 140, Issue:2

    Topics: Aged; Coronary Angiography; Coronary Vasospasm; Female; Heart Valve Prosthesis Implantation; Humans;

2010
[The use of milrinone in a patient with mitral regurgitation and severe pulmonary hypertension: a case report].
    Masui. The Japanese journal of anesthesiology, 2003, Volume: 52, Issue:7

    Topics: Aged; Female; Humans; Hypertension, Pulmonary; Milrinone; Mitral Valve; Mitral Valve Insufficiency;

2003
Predictors of inotrope use during separation from cardiopulmonary bypass.
    Journal of cardiothoracic and vascular anesthesia, 2004, Volume: 18, Issue:4

    Topics: Cardiopulmonary Bypass; Cardiotonic Agents; Catecholamines; Coronary Artery Bypass; Dopamine; Echoca

2004
Application of papillary muscle sling concept in an infant as a biological bridge to transplantation.
    The Annals of thoracic surgery, 2005, Volume: 79, Issue:1

    Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Combined Modality Therapy; Disease Progression; Heart F

2005
[A case of continuous infusion of milrinone during continuous venovenous hemofiltration causing high plasma concentration of milrinone].
    Masui. The Japanese journal of anesthesiology, 2005, Volume: 54, Issue:2

    Topics: Aged; Female; Heart Valve Prosthesis Implantation; Hemofiltration; Humans; Kidney Failure, Chronic;

2005
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
    Circulation, 2006, Jul-04, Volume: 114, Issue:1 Suppl

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality

2006